Clinical Trial News and Research

RSS

Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress.

18 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Vitamin D: sunshine, diet and supplements - cancer prevention and therapy

Vitamin D deficiency is common and cancer risk is higher among those individuals with low vitamin D levels, according to an analysis of research which will be presented at a symposium by Donald L.

17 Apr 2007

Brain tumor vaccine shows promise

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.

17 Apr 2007

New hope for spinal cord injury sufferers

Spinal cord injury (SCI) is one of the most significant forms of neurotrauma with major economic and social impact.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Potential treatments for mouth ulcers

The drug pentoxifylline appears to have limited benefit in the first-line treatment of mouth ulcers due to recurrent apthous stomatitis, according to a report in the April issue of Archives of Dermatology.

17 Apr 2007

Chondroitin for arthritis just doesn't work

According to Swiss researchers the dietary supplement chondroitin is no better than a placebo at easing the hip and knee pain of arthritis and they believe its use should be discouraged.

17 Apr 2007

Human Genome Sciences reports results of phase 2b trial of Albuferon

Human Genome Sciences has reported results at Week 12 following the completion of therapy (SVR12) in a Phase 2b clinical trial of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens.

16 Apr 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007

Gleevec shows great promise in preventing cancer recurrence

Gleevec, a pill developed in conjunction with the Oregon Health & Science University Cancer Institute is again showing excellent results in preventing a cancer recurrence.

15 Apr 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

Gleevec decreases cancer recurrence for GIST

Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.

15 Apr 2007

Cytokinetics initiates of phase II clinical trial for CK-1827452

Cytokinetics has announced the initiation of a Phase II clinical trials program evaluating CK-1827452, a novel cardiac myosin activator for the potential treatment of patients with either acutely decompensated or chronic heart failure.

15 Apr 2007

Updated guidelines for early management of adults with ischemic strok

Intravenous delivery of an approved clot-busting drug remains the most beneficial proven intervention for ischemic stroke, according to updated American Heart Association/American Stroke Association guidelines published in Stroke: Journal of the American Heart Association.

14 Apr 2007

Oncolytics Biotech to proceed with phase II Sarcoma trial

Oncolytics Biotech has announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN in patients with various sarcomas that have metastasized to the lung.

11 Apr 2007

Pharmacopeia announces positive results in hypertension and diabetic nephropathy trial

Pharmacopeia ( NASDAQ:PCOP ) , an innovator in the discovery and development of novel small molecule therapeutics, today announced positive results from the initial Phase 1 clinical trial of PS433540, the company's lead internal product candidate for the treatment of hypertension and diabetic nephropathy.

11 Apr 2007

Experimental flu vaccine produced using insect cells shows promise

An influenza vaccine produced with the use of insect cells appeared safe and produced an immunogenic response in healthy adults, suggesting promise as an alternative to using embryonated eggs for the development of influenza vaccine, according to a preliminary study in the April 11 issue of JAMA.

11 Apr 2007

Study shows beneficial effects of pneumococcal conjugate vaccines in children

Routine infant immunisation with pneumococcal conjugate vaccine (PCV7) has caused a 39% fall in all-cause pneumonia hospital admission rates for American children aged under two years, according to an Article published in this week's edition of The Lancet.

8 Apr 2007